TP53 and lung carcinoma: Among lung cancer patients, EGFR mutations (44 %), followed by TP53 (43 %), CDKN2A (9 %), PIK3CA (9 %), and BRAF (6 %).Tissue–liquid biopsy concordance was observed in 36 of 96 cases for which baseline tissue NGS data was available.